



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

MAY 20 1997

Food and Drug Administration
2098 Gaither Road
Rockville MD 20850WARNING LETTERVIA FEDERAL EXPRESS

Ref:OC:I1-1754

Mr. Marvin Loeb
Chairman and CEO
Trimedyne, Inc.
2801 Barranca Road
Irvine, California 92714

Dear Mr. Loeb:

This letter is written to advise you of two items of noncompliance with the Federal laser product performance standard encountered during review of the Model 1500-A Ho:YAG laser product report dated April 17, 1997, Accession Number 9021729-22.

1. 21 CFR 1040.11(a)(2). The Model 1500-A Operation manual lacks calibration procedures for the laser's internal measurement system and schedule for calibration. Although we would not object to your inclusion of a statement to the effect that only authorized service personnel may perform the procedure, the requirement is clear that the instructions must be supplied to the user.
2. 21 CFR 1040.10(h)(1)(i). The Operation manual lacks adequate user information to enable users to readily comply with accepted user safety standards. See the August 11, 1995, notice to industry, enclosed.

Section 538(a) of the Federal Food, Drug, and Cosmetic Act (the Act), Chapter V, Subchapter C (formerly the Radiation Control for Health and Safety Act of 1968) prohibits any manufacturer from certifying or introducing into commerce laser products which do not comply with the standard. This section also prohibits any manufacturer from failure to establish and maintain required records or to submit required reports. Failure to respond to this letter may be considered to be in violation of section 538(a)(4) of the Act.

Page 2 - Mr. Marvin Loeb

This letter is not intended to be an all-inclusive list of deficiencies. It is your responsibility to ensure adherence to each requirement of the Act and regulations. The specific violations noted in this letter may be symptomatic of serious underlying problems in your firm's manufacturing and quality assurance programs. You are responsible for investigating and determining the causes of the violations identified by the Food and Drug Administration (FDA). If the causes are determined to be systemic problems you must promptly initiate permanent corrective actions. Federal agencies are advised of the issuance of all Warning Letters about devices so that they may take this information into account when considering the award of contracts.

You should take prompt action to correct these deviations. Failure to promptly correct these deviations may result in regulatory action being initiated by the FDA without further notice. These actions may include, but are not limited to, injunction and/or imposition of civil penalties as provided for in section 539.

You must respond in writing within 15 working days of receipt of this letter to one of the options listed below. In your response you must also provide the number of the referenced products which have been produced and the number of such products that have left the place of manufacture. In addition, if the product distribution was confined to specific geographical areas of the United States, please specify those areas.

1. Refutation - You may submit your views and evidence to establish that the alleged noncompliances do not exist.
2. Exemption Request - You may request an exemption from user and dealer/distributor notification and from obligation to correct the violative products. Your request must include the grounds upon which such exemption is requested (see 21 CFR 1003.30 and 1003.31).
3. Purchaser Notification and Corrective Action - If you neither refute the noncompliance nor request an exemption, then you must: (a) notify purchasers and dealers/distributors of the violative products as specified in 21 CFR 1003.10(b), and (b) submit a written corrective action plan (CAP) to fulfill your obligation under 21 CFR 1004.1 to repair, replace, or refund the cost of the violative products.

Page 3 - Mr. Marvin Loeb

- a. Notification Letter - Requirements for preparation of notification letters are prescribed in 21 CFR 1003.21 and 1003.22. A copy of the notification letter(s) sent to purchasers and dealers must also be sent to the FDA. It is recommended that you submit a draft of this letter to us for review.
- b. Corrective Action Plan - Instructions for preparation of a CAP may be found in 21 CFR 1004.2, 1004.3, or 1004.4.

If you request additional time to prepare your refutation, notification, CAP, or evidence to support a requested exemption, you must provide the reasons for any delays and a reasonable target date for the full submission of your response. Be aware that if an acceptable CAP cannot be prepared promptly, you may be required to proceed with interim notification to affected persons as required by 21 CFR 1003.11(c) and 1003.21. Therefore, you are encouraged to immediately begin your preparation of accurate user location lists.

When you have completed any production changes necessary to assure compliance of future units and you have submitted the required reports and report supplements, you may resume introduction of these products into commerce.

Additionally, we request further clarification on the internal measurement system and its displayed values. The operator's manual instructs the user to disregard the total parameter number. Further, it states that "The values on the laser display do not reflect the actual laser output." The user is instructed to make adjustments based on the power/energy and pulse measurements made with the external power meter. It is unclear what the displayed values on the display screen mean and why they can't be meaningful to the doctor. We are concerned that users may inadvertently misinterpret them and make adjustments, placing the patient in danger. Please explain.

Your response should be sent to: General Surgery Devices Branch, Division of Enforcement I (HFZ-323), Office of Compliance, Center for Devices and Radiological Health, 2098 Gaither Road,

Page 4 - Mr. Marvin Loeb

Rockville, Maryland 20850. Please send a copy of your response to: Compliance Branch (HFR-PA240), Food and Drug Administration, 19900 MacArthur Boulevard, Suite 300, Irvine, California, 92612. If you have further questions on these requirements, please contact Cory Tylka of the General Surgery Devices Branch at (301) 594-4595.

Sincerely yours,

for Lillian J. Gill

Lillian J. Gill
Director
Office of Compliance
Center for Devices and
Radiological Health

CC: Ms. Susan H. Gamble
Vice President, Regulatory Affairs
and Quality Assurance
Trimeddyne, Inc.
2801 Barranca Road
Irvine, California 92714

4/27/74